Search results
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 1 day agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 2 hours agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 6 hours agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 1 day agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 23 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 1 day agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 2 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 2 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Pfizer’s Phase III DMD gene therapy trial misses primary endpoint
Clinical Trials Arena via Yahoo Finance· 1 day agoPfizer has reported that its Phase III CIFFREO clinical trial of investigational mini-dystrophin...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 1 day agoThe firm's stance comes after Pfizer (NYSE:PFE) announced its phase 3 trial for a gene therapy...